News

News 01.02.2024 Zurich, Switzerland - 31.01.2024 Neurimmune aims to develop aducanumab-based therapeutics that can be subcutaneously administered Neurimmune announced today that it regained global rights to aducanumab, a recombinant human antibody developed to deplete brain amyloid. Aducanumab was granted FDA accelerated approval for the treatment of Alzheimer’s disease. Neurimmune licensed its antibody aducanumab for...

News 01.02.2024 Schlieren (Zurich), Switzerland, January 31, 2024 – Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced clearance of a 510(k) submission from the U.S. Food and Drug Administration (FDA) related to its MagnetOs™ Granules. The Company also announced clearance to market in New Zealand...

News 27.01.2024 Securecell AG has released a new version of Lucullus®. The latest update follows version 23.0.0 and is named version 24.1.0 based on the new version naming convention. With version 24.1.0, many new features were implemented, and a long list of bugs was resolved. The most important changes are: After a thorough...

News 24.01.2024 ZURICH, Switzerland and NEWTON, Massachusetts, January 23, 2024 (GlobeNewswire). Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the operational readiness of its new proteomics facility in Massachusetts. This US expansion facilitates access to select proteomics contract research organization (CRO) services for our US biopharma customers. The Massachusetts...

News 24.01.2024 Schlieren, Switzerland January 23rd, 2024 – EraCal Therapeutics Ltd. today announced that it has entered into a collaboration and license agreement with Novo Nordisk A/S to develop and commercialize EraCal’s oral, small molecule program. The asset was discovered with EraCal’s platform technology and is believed to target a novel mechanism...